Develops innovative therapies specifically for liver diseases. Focuses on non-alcoholic steato-hepatitis (NASH) as a primary therapeutic area. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
Business Quality: Profit power and business quality trail similar companies in the sector.
An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Our checks did not surface a specific strength to highlight here.
A loss of $10.3M against $0 in annual sales.
At the current pace of spending, the cash lasts about 1.8 years. After that, the company needs to find new money.
On our five-subject report card, GLMD sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: GLMD is a high-risk stock — not yet profitable, and its future rides on its product catching on.
Not covered, because the filings we hold do not carry it: the revenue breakdown.